Pramlintide
Also known as: 25B-Amylin, AC137, AM-100, Pramlintide acetate, Symlin, SymlinPen
Source Pramlintide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pramlintide is a synthetic analog of human amylin used as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes to improve postprandial glucose control.
Mechanism of Action
Activates amylin receptors to slow gastric emptying, suppress postprandial glucagon secretion, and promote satiety, thereby improving postprandial glucose control.
Routes of Administration
Goals & Uses
- Weight managementBody CompositionModerate
- HbA1c reductionGlycemic ManagementHigh
- Satiety inductionAppetite RegulationModerate
- Glucagon suppressionGlycemic ManagementHigh
- Glycemic control in type 2 diabetesMetabolicHigh
- Glycemic control in type 1 diabetesMetabolic / EndocrineHigh
- Postprandial glucose controlGlycemic ManagementHigh
Contraindications
- Hypersensitivity to pramlintide or excipientsImmunologicalHigh
- Poor adherence to insulin regimenBehavioralModerate
- Severe gastroparesisGastrointestinalModerate
- Confirmed gastroparesisGastrointestinalHigh
- Hypersensitivity to pramlintide or any excipientsAllergyHigh
- Hypoglycemia unawarenessEndocrine/MetabolicHigh
Adverse Effects
- Severe hypoglycemiaEndocrine/MetabolicUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Hypoglycemia (when combined with insulin)MetabolicCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- AnorexiaMetabolicCommon
Drug Interactions
- Insulin (mealtime)High
- InsulinHighMay increase risk of low blood sugar
- Other glucose‑lowering agentsModerate
- Alpha-glucosidase inhibitors (e.g., acarbose)Moderate
- Oral medications requiring rapid GI absorption (e.g., analgesics, antibiotics)Moderate
- Anticholinergic agentsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patients (<18 years)AgeRelative
- Pediatric patients (<16 years)AgeAbsolute
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Adjunct to insulin therapy in type 1 diabetes, Adjunct to insulin therapy in type 2 diabetesEMA approval.
- United StatesApprovedApproved: Adjunct to insulin therapy in type 1 diabetes, Adjunct to insulin therapy in type 2 diabetesFDA approval 2005.
- United KingdomApprovedApproved: Adjunct to insulin therapy in type 1 diabetes, Adjunct to insulin therapy in type 2 diabetesMHRA approval.
FDA‑approved (2005) for type 1 and type 2 diabetes; also approved in EU and UK. Marketed under the brand name Symlin.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Pramlintide?
Pramlintide is a synthetic analog of human amylin used as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes to improve postprandial glucose control.
What is Pramlintide used for?
Pramlintide is educationally associated with: Weight management, HbA1c reduction, Satiety induction, Glucagon suppression, Glycemic control in type 2 diabetes, Glycemic control in type 1 diabetes, Postprandial glucose control. Educational only — not medical advice.
How is Pramlintide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Pramlintide?
Reported adverse effects include: Severe hypoglycemia, Injection site reactions, Headache, Hypoglycemia (when combined with insulin), Nausea, Vomiting, Anorexia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pramlintide?
Recorded contraindications: Hypersensitivity to pramlintide or excipients, Poor adherence to insulin regimen, Severe gastroparesis, Confirmed gastroparesis, Hypersensitivity to pramlintide or any excipients, Hypoglycemia unawareness. Consult a qualified clinician before use.